Importantly, studies suggest that these effects may be long-lasting, as liver fibrosis remained significantly reduced from baseline after 3 years [45] and 5 years [46,47] in patients with T2DM and MASLD who take SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.